About US
PRODUCTS
EASYWELL易威生醫
About US
Vision and Mission
History
Corporate Executives
Global Locations
PRODUCTS
Pharmaceuticals
News
News
Events
HR
Career
Job Opportunities
Join EASYWELL
Investors
Financial Information
Shareholder Services
Corporate Governance
Sustainability
IR Contacts
Favorites
Sitemap
EN
TW
TOP
首頁橫幅
BUSINESS GROUPS
Pharmaceuticals
TULEX has a state-of-the art cGMP facility that integrates research and development to manufacture and commercialize their products.
news
25
2025.06
Tulex Pharmaceuticals, the U.S. subsidiary,announced that TLX-047, an anti-inflammatory drug,has received FDA approval notification.
more
01
2025.05
代⼦公司美國Tulex Pharmaceuticals公告,共同開發新藥(505(b)(2))液態⼝服治療尿崩症藥品,已向美國FDA 提出新劑型新藥查驗登記申請(NDA)
more
17
2024.12
本公司及子公司Tulex Pharmaceuticals Inc.共同與合作夥伴簽訂TLX-050神經系統用藥之合作開發合約,新增第三方合作夥伴
more
27
2024.09
HH-001沙庫巴曲纈沙坦鈉片(悅欣妥)大陸市場擴展狀況
more
18
2024.03
孫公司江蘇華瀚醫藥科技有限公司HH-001沙庫巴曲纈沙坦鈉片(悅心妥)重磅上市
more
29
2023.10
代孫公司江蘇華瀚醫藥科技有限公司公告HH-001沙庫巴曲纈沙 坦鈉片藥品接獲中國藥監局通知領取藥證
more
15
2023.05
代美國子公司Tulex Pharmaceuticals公告共同開發之TLX-032新藥獲美國FDA核准進行二期臨床試驗
more
15
2023.03
代美國子公司Tulex公告與美國Eton Pharmaceuticals簽署505(b)(2)新藥開發之獨家技術授權及CDMO合約,開發治療兒童罕見疾病之藥物,並於藥品成功上市後獲得淨銷售分潤。
more
22
2022.09
代子公司美國Tulex Pharmaceuticals Inc.公告,共同開發新藥(505(b)(2))液態口服劑型癲癇藥品(研發代號:ET-101)通過美國發明專利並完成登錄於美國FDA橘皮書(The Orange Book)
more